- Home
- KRON
KRON
Kronos Bio Inc.
as 12-17-2024 4:00pm EST
Kronos Bio Inc is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes through a precision medicine plan by targeting dysregulated transcription. The company operates in one business segment, the development of biopharmaceutical products.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | SAN MATEO |
| Market Cap: | 60.3M | IPO Year: | 2020 |
| Target Price: | $1.63 | AVG Volume (30 days): | 384.9K |
| Analyst Decision: | Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.44 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.69 - $1.60 | Next Earning Date: | 11-13-2024 |
| Revenue: | $9,864,000 | Revenue Growth: | 146.48% |
| Revenue Growth (this year): | 62.21% | Revenue Growth (next year): | N/A |
Latest Kronos Bio Inc. News
KRON Breaking Stock News: Dive into KRON Ticker-Specific Updates for Smart Investing
Simply Wall St.
15 days ago
Discover 3 US Penny Stocks With Market Caps Over $40M
Pharmaceutical Technology
20 days ago
Kronos Bio announces interim CEO and workforce cuts of 83%
Benzinga
21 days ago
Kronos Bio Shakes Up Leadership - Cuts 83% Of Workforce Amid Strategic Overhaul
MT Newswires
21 days ago
Kronos Bio Names Deborah Knobelman Interim CEO, Cuts Workforce by 83%
GlobeNewswire
21 days ago
Kronos Bio Announces CEO Transition and Reduction in Force
BioPharma Dive
21 days ago
Kronos, Idorsia plan layoffs; PTC shelves ALS drug
Simply Wall St.
a month ago
Kronos Bio Third Quarter 2024 Earnings: Beats Expectations
GlobeNewswire
a month ago
Kronos Bio Highlights Preclinical Data that Show p300 KAT Inhibitors Reduce Inflammation in an Oral Presentation at ACR Convergence 2024
Compare KRON vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "KRON Kronos Bio Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.